Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (IMPALA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02702180
Recruitment Status : Active, not recruiting
First Posted : March 8, 2016
Last Update Posted : December 31, 2018
Sponsor:
Information provided by (Responsible Party):
Savara Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : March 2019
  Estimated Study Completion Date : September 2019